Home Alzheimer’s Disease First-Line Nivolumab Plus Ipilimumab Improves OS Versus Chemo in Patients with Metastatic...

First-Line Nivolumab Plus Ipilimumab Improves OS Versus Chemo in Patients with Metastatic Uveal Melanoma

A phase 2 study published in the Journal of Clinical Oncology found that in the first-line setting for patients with metastatic uveal melanoma, nivolumab (Opdivo) plus ipilimumab (Yervoy) demonstrated a modest improvement in overall survival compared with historical benchmarks of chemotherapy.

In addition, the toxicity profile of the treatment combination was found to be manageable and did not differ from that in observed in patients with cutaneous melanoma, for which treatment with nivolumab plus ipilimumab is already approved.

“These results provide a strong rationale for further research on immunotherapy treatment combinations in [uveal melanoma],” wrote the study authors, who were led by José María Piulats, MD, PhD.

In this multicenter, open-label, single-arm phase 2 trial (NCT02626962) led by the Spanish Multidisciplinary Melanoma Group (GEM), treatment-naïve patients who…

Continue Reading to the Source


Please enter your comment!
Please enter your name here

Most Popular

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is...

FDA Grants Breakthrough Therapy Designation to Tipifarnib for Treatment of HRAS-Mutant HNSCC

The FDA has granted breakthrough therapy designation to the investigational drug tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and...

Treatment with PARP Inhibitors Increased Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia

Patients treated with PARP inhibitors saw an increased risk of myelodysplastic syndrome and acute myeloid leukemia (AML) versus patients treated with placebo, according to...

Salma Jabbour, MD, on Next Steps for the KEYNOTE-799 Study

The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey discussed how she hopes the results of the KEYNOTE-799 study...

Recent Comments